gip/glp-1 receptor agonist mechanism of action The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology This is your presentation title

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

What is Retatrutide

Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs)have emerged as a transformative class of medications in the management oftype 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events

Due to the bodys natural tendency to restore its former weight, many people regain their lost weight when they stop using GLP-1 drugs.

Then, we will discuss the approaches that can increase the endogenous production of GLP-1 through various stimuli